2,7-bis[(2R)-1-methylpyrrolidin-2-ylmethoxy]-fluoren-9-one | 861118-07-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2,7-bis[(2R)-1-methylpyrrolidin-2-ylmethoxy]-fluoren-9-one
• 英文别名: 2,7-bis[[(2R)-1-methylpyrrolidin-2-yl]methoxy]fluoren-9-one
• CAS: 861118-07-2
• 化学式: C₂₅H₃₀N₂O₃
• 分子量: 406.525
• InChiKey: MPSVSIQCCLCJPT-QZTJIDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,7-bis[(2R)-1-methylpyrrolidin-2-ylmethoxy]-fluoren-9-one 、 对甲苯磺酸一水合物 以 乙酸乙酯 、 乙醇 为溶剂， 反应 16.0h， 以to afford the title compound (68 mg, 0.09 mmol; 74%)的产率得到2,7-Bis[(2R)-1-methylpyrrolidin-2-ylmethoxy]-fluoren-9-one di-p-toluenesulfonate
  参考文献：
  名称：

  Amino-substituted tricyclic derivatives and methods of use

  摘要：

  式(I)的化合物中，其中A和B是氨基取代的侧链，Y1和Y2形成不同的三环核心，Xa和Xb是C、CH或N，如本文所定义，Rx是可选的取代基。式(I)的化合物和组合物被考虑用于治疗由α7 nAChR配体预防或缓解的疾病或疾病状态，其中包括式(I)和其他三环衍生物的化合物。本文还描述了使用氨基取代的三环衍生物的方法。

  公开号：

  US07951791B2
• 作为产物：
  描述：

  2,7-二羟基-9-芴酮 、 N-甲基-D-脯氨醇 在 diphenylphosphinopolystyrene 、 偶氮二甲酸二叔丁酯 作用下， 生成 2,7-bis[(2R)-1-methylpyrrolidin-2-ylmethoxy]-fluoren-9-one
  参考文献：
  名称：

  SAR of α7 nicotinic receptor agonists derived from tilorone: Exploration of a novel nicotinic pharmacophore

  摘要：

  The well-known interferon-inducer tilorone was found to possess potent affinity for the agonist site of the alpha 7 neuronal nicotinic receptor (K-i = 56 nM). SAR investigations determined that both basic sidechains are essential for potent activity, however active monosubstituted derivatives can also be prepared if the flexible sidechains are replaced with conformationally rigidified cyclic amines. Analogs in which the fluorenone core is replaced with either dibenzothiophene-5,5-dioxide or xanthenone also retain potent activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.126

文献信息

• Amino-Substituted Tricyclic Derivatives and Methods of Use
  申请人：Schrimpf Michael R.

  公开号：US20080161281A1

  公开（公告）日：2008-07-03

  Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y 1 and Y 2 form various tricyclic cores, X a and X b are C, CH, or N, as defined herein, and R x is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.

  式(I)的化合物中，A和B是胺基取代的侧链，Y1和Y2形成各种三环核心，Xa和Xb为C、CH或N，如本文所定义，R为可选取代基。本文考虑了式(I)的化合物和组合物，以及用于治疗α7 nAChR配体包括式(I)化合物和其他三环衍生物的条件或障碍的方法。本文还描述了使用氨基取代的三环衍生物的方法。
• AMINO-SUBSTITUTED TRICYCLIC DERIVATIVES AND METHODS OF USE
  申请人：ABBOTT LABORATORIES

  公开号：EP1711463A2

  公开（公告）日：2006-10-18
• US7365193B2
  申请人：——

  公开号：US7365193B2

  公开（公告）日：2008-04-29
• US7951791B2
  申请人：——

  公开号：US7951791B2

  公开（公告）日：2011-05-31
• [EN] AMINO-SUBSTITUTED TRICYCLIC DERIVATIVES AND METHODS OF USE<br/>[FR] DERIVES TRICYCLIQUES A SUBSTITUTION AMINO ET LEURS PROCEDES D'UTILISATION
  申请人：ABBOTT LAB

  公开号：WO2005077899A2

  公开（公告）日：2005-08-25

  Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.